Cancer Health Outcomes & Control Research Program
The Cancer Health Outcomes and Control Program conducts research aimed at reducing the burden of cancer across the entire cancer care continuum. The research efforts of this interdisciplinary, collaborative program center on the themes of:
- Prevention and Early Detection
- Treatment-Related Outcomes
- Survivorship and Palliative Care
The Cancer Health Outcomes and Control Program aims to achieve the goal of reducing the cancer burden through:
Prevention & Early Detection
Establishing and further developing population and community-based resources for research into prevention and early detection
Identifying environmental, sociobehavioral and genetic factors that affect short- and long-term outcomes
Survivorship & Palliative Care
Understanding the scope of and developing interventions to prevent or ameliorate adverse long-term patient-centered outcomes following cancer diagnosis and treatment
Assessing the magnitude and determinants of disparities in cancer control and outcomes associated with age, race, gender, geography and other group characteristics and developing interventions to decrease such disparities
Designing and testing healthcare practices and policies that improve access to and delivery of care to minimize the burden of cancer
Meet the Program Members
Debra Friedman, M.D., M.S., David Penson, M.D., M.P.H., and Pierre Massion, M.D., co-lead the Cancer Health Outcomes and Control program. The program maintains close alliances with other cancer center programs, including population science partner program, Cancer Epidemiology, and the basic and clinical science programs. Extensive collaborations with community partners—including Meharry Medical College, Tennessee State University, federally qualified community health centers and oncologists at affiliate institutions, and other academic centers—extend the program's impact in the community and foster multi-institution research.
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): A multicentre, randomised, double-blind, phase 3 trial.
Tombal, B., Saad, F., Penson, D. (CO), Hussain, M., Sternberg, C.N., Morlock, R., Ramaswamy, K., Ivanescu, C. & Attard, G
Lancet Oncol 20(4):556-569, 2019; PMID:30770294.
Considering quantity and quality of life in metastatic castration-naive prostate cancer.
Penson DF (CO).
Lancet Oncol. 2018 FEB 19(2):153-154 PMID:29326027.
Smoking Cessation Pharmacotherapy, Even Without Counseling, Remains a Cornerstone of Treatment
Tindle HA (CO), Greevy RA
J. Natl. Cancer Inst. 2017 DEC 21 PMID:29281038
Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years
Barocas D (CO), Alvarez J, Resnick MJ (CO), Koyama T (NP), Hoffman KE, Tyson MD, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF (CO)
JAMA 2017 MAR 21 317(11):1126-1140 PMID:28324093
Success and Failure in the Insurance Exchanges
Garthwaite C, Graves JA (CO)
N. Engl. J. Med. 2017 MAR 9 376(10):907-910 PMID:28146412
Multiple Myeloma Mortality in Relation to Obesity Among African Americans.
Sonderman JS, Bethea TN, Kitahara CM, Patel AV, Harvey C, Knutsen SF, Park Y, Park SY, Fraser GE, Teras LR, Purdue MP, Stolzenberg-Solomon RZ, Gillanders EM, Palmer JR, Kolonel LN, Blot WJ (CE, CO).
J. Natl. Cancer Inst. 2016 OCT 108(10) PMC5858251.